On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies.
Open Access
- 1 January 1995
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 95 (1) , 309-316
- https://doi.org/10.1172/jci117657
Abstract
Phosphatidylethanolamine (PE) is an important membrane component for supporting activated protein C anticoagulant activity but has little influence on prothrombin activation. This difference constitutes a potential mechanism for selective inhibition of the protein C anticoagulant pathway by lupus anticoagulants and/or antiphospholipid antibodies. In this study, we demonstrate that the presence of PE augments lupus anticoagulant activity. In the plasma of some patients with lupus anticoagulants, activated protein C anticoagulant activity is more potently inhibited than prothrombin activation. As a result, in the presence of activated protein C and PE, these patient plasmas clot faster than normal plasma. Patients with minimal lupus anticoagulant activity are identified whose plasma potently inhibits activated protein C anticoagulant activity. This process is also PE dependent. In three patient plasmas, these phenomena are shown to be due to immunoglobulins. The PE requirement in the expression of activated protein C anticoagulant activity and the PE dependence of some antiphospholipid antibodies provide a mechanistic basis for the selective inhibition of the protein C pathway. Inhibition of activated protein C function may be a common mechanism contributing to increased thrombotic risk in certain patients with antiphospholipid antibodies.Keywords
This publication has 33 references indexed in Scilit:
- Anticoagulant protein C pathway defective in majority of thrombophilic patients.1993
- Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state.1993
- Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?1993
- Beta 2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants.1993
- Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems.Journal of Biological Chemistry, 1986
- Inhibition of Protein C Activation by Endothelial Cells in the Presence of Lupus AnticoagulantNew England Journal of Medicine, 1986
- An IgM Lupus Anticoagulant that Neutralizes the Enhancing Effect of Phospholipid on Purified Endothelial Thrombomodulin Activity-A Mechanism for ThrombosisThrombosis and Haemostasis, 1986
- Changes in membrane phospholipid distribution during platelet activationBiochimica et Biophysica Acta (BBA) - Biomembranes, 1983
- Lupus anticoagulants.1982
- Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant.Journal of Clinical Investigation, 1980